Oncology · For Medical Affairs

What clinicians say about clinical trials, and why.

How clinicians read a trial in podcasts, video and on social media: what they find convincing, where they differ and what they still question, with every view linked to its source.

Find your trial Get a free report Connect your AI agent →

Explore the report previews

View for

/

Try: · · ·

Indication

Trial	Indication	Total statements	Size	Checked	Preview
Krascendo 1 NCT06497556 · Hoffmann-La Roche Deep314 statements · 101 from 39 confirmed cliniciansPreview →	previously treated KRAS G12C-positive non-small cell lung cancer	314 Of these, 101 from 39 confirmed clinicians	Deep	Nov 1, 2026	Preview
KEYNOTE-B49 NCT04895358 · Merck Sharp & Dohme LLC Focused74 statements · 27 from 9 confirmed cliniciansPreview →	HR+/HER2- locally recurrent inoperable or metastatic breast cancer	74 Of these, 27 from 9 confirmed clinicians	Focused	Oct 31, 2026	Preview
PERSEE NCT04547504 · University Hospital, Brest Standard217 statements · 155 from 44 confirmed cliniciansPreview →	first-line advanced NSCLC with PD-L1 ≥50%	217 Of these, 155 from 44 confirmed clinicians	Standard	Nov 3, 2026	Preview
FOURLIGHT-1 NCT06105632 · Pfizer Focused94 statements · 31 from 13 confirmed cliniciansPreview →	HR-positive/HER2-negative advanced/metastatic breast cancer after CDK4/6 inhibitor-based therapy	94 Of these, 31 from 13 confirmed clinicians	Focused	Nov 1, 2026	Preview
G-HOPE-001 NCT06238843 · Innovent Biologics (Suzhou) Co. Ltd. Focused99 statements · 38 from 7 confirmed cliniciansPreview →	CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma	99 Of these, 38 from 7 confirmed clinicians	Focused	Nov 1, 2026	Preview
AMPLIFY-7P NCT05726864 · Elicio Therapeutics Standard255 statements · 51 from 10 confirmed cliniciansPreview →	KRAS/NRAS-mutated solid tumors	255 Of these, 51 from 10 confirmed clinicians	Standard	Nov 4, 2026	Preview

6 of 108 reports

curl

# What Erudio is and how to query it
curl https://www.erudio.com/llms.txt

# Every report, with counts, version and links
curl https://www.erudio.com/catalog.json

# One report as JSON or Markdown
curl https://www.erudio.com/reports/{slug}.json

mcp config

{
  "mcpServers": {
    "erudio": { "url": "https://mcp.erudio.com/mcp" }
  }
}

# then ask your agent:
# search_reports({ "drug": "ifinatamab-deruxtecan" })

108 published reports

all reports and trials →

Free report · IDeate-Lung01

Check our work before you buy.

Report previewFirst 4 of 7 findings

Question clinicians left open

What do clinicians say they still need to see about ILD/pneumonitis risk with ifinatamab deruxtecan to judge its benefit–risk balance in pretreated extensive-stage small cell lung cancer?

01Clinicians discuss tolerability and ILD vigilance; one account argues I-DXd’s risks outweigh benefits, another attributes withdrawal to insufficient evidence.
02Clinicians discuss the need for randomized evidence; accounts debate the trial's regulatory status and conditional paths to future approval
03Clinicians discuss I-DXd responses, dosing and toxicity, including early PFS/OS dissent, durability concerns and a request for randomized evidence.
04One interview presents brain activity as potentially treatment-changing, with a small subgroup explicitly qualified

274 verified statements (91 from clinicians verified by NPI or staff page) from 73 commentary sources · 7 findings · commentary checked Nov 3, 2026Open the report →

What an AI agent made from this report, for 9 Medical Affairs jobs: see the use cases.

One trial, read three ways.

Every report has the same three parts: for you, for the colleagues you forward it to, and for your AI agent.

For you and your VP

Executive summary

The two-minute read: how the clinicians who discussed the trial read it, where they differ, and the question they left open. A PDF to forward.

For your Medical Directors

Detailed analysis

The reasoning, disagreements, qualifications and counterviews behind each finding, to read in your browser.

For your AI agent

Structured evidence

Every verified statement with its speaker, date, short quote and link, as JSON and through the Erudio MCP, so your agent can check any finding.

Every license includes CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers; public previews do not. Shown for transparency and conflict-of-interest review; not for targeting or outreach. Everything a report holds

A single report, agent included

Buy the current edition, or follow the trial for 3, 6 or 12 months and get each new edition with a note of what changed. We automatically check subscribed trials for new commentary every week. No enterprise contract. Trials without a report are built within 24 hours of your order.

Browse reports Pricing

Enterprise MCP, the whole corpus

Your agents search all the clinician podcasts, videos and posts we index, look up clinicians, and read every report your organization licenses.

Enterprise MCP Request a pilot

Trust

Public sources only. Every statement linked. Every edition versioned, with corrections in the open.

How a report is built

Reports are built by AI and checked by automated review. Every report keeps what clinicians said apart from what the primary evidence establishes, and never turns commentary into an efficacy verdict or a consensus. Methods
Built by Audun Utengen and Tom Lee, who have served pharmaceutical Medical Affairs teams for more than a decade at Symplur and Real Chemistry. About us
Security-only SOC 2 Type II report, available under NDA. Trust center